Aurora Cannabis (ACB)(ACBFF) has a market capitalization of 5.4 billion Canadian dollars, which is comparable to that of Canopy Growth Corporation (WEED). Over the recent one-year period, Aurora Cannabis stock has risen 330.0% to 11.50 Canadian dollars per share on February 6, 2018.
Aurora Cannabis has been in the news lately with its acquisition of CanniMed (CMED) and its recent investment in Liquor Stores N.A. You can read more about these investments in the following articles:
The current consensus mean rating for Aurora Cannabis stood at 1.8, which translated into an overall “buy” recommendation. Out of the four analysts surveyed by Reuters, two have a “strong buy” recommendation on the stock while one analyst has a “buy” recommendation for the next-12-month period.
One analyst has a “hold” recommendation on the stock while none have either a “sell” or a “strong sell” recommendation on the company. Unlike Canopy Growth (WEED) and Aphria (APHQF), fewer analysts have coverage (MJX) on Aurora Cannabis.
The current consensus mean price target on Aphria stood at 9.00 Canadian dollars, which is significantly below the company’s price of 11.50 Canadian dollars on February 6. The median price target on Aurora Cannabis stood at 8.30 Canadian dollars on the same day.
We’ll look at MedReleaf’s (LEAF) price target and ratings next.